Brief: Matinas Biopharma- Non-Inferiority Trial Will Enroll About 216 Patients With Primary Endpoint Of All-Cause Mortality
20/02/2024 12:36
Feb 20 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA SUCCESSFULLY REACHES AGREEMENT WITH FDA
FOR A
SINGLE PHASE 3 REGISTRATION TRIAL TO SUPPORT AN NDA FOR MAT2203
FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS
* MATINAS BIOPHARMA HOLDINGS INC - NON-INFERIORITY TRIAL
WILL
ENROLL APPROXIMATELY 216 PATIENTS WITH PRIMARY ENDPOINT OF
ALL-CAUSE MORTALITY AT DAY 42
Source text for Eikon: ID:nGNX6nLbr8
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing